Familial Risk and Surveillance of Colon and Rectum Malcolm Dunlop Academic Coloproctology & Colon Cancer Genetics Group University of Edinburgh & Western.

Slides:



Advertisements
Similar presentations
Hereditary GI Cancer Syndromes: Keys to identify high risk patients
Advertisements

Universal Screening of Lynch Syndrome Heather Hampel, MS, CGC Clinical Associate Professor, Division of Human Genetics.
1 An Update on Evolving Colorectal Screening Issues May 19, 2011 This first part today will be presented by: Stanley H. Weiss, MD, FACP, FACE  Professor,
Introduction to Cancer Genetics
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy Supervisor: 邱宗傑 主任 Presented by 郭政裕 總醫師 NEJM, Sep 19, 2013.
Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
A few thoughts on cancer and cancer family syndromes Pamela McGrann, MD. Department of Medical Genetics.
COLORECTAL BLEEDING: a multidisciplinary approach Torino, 31 marzo-1 aprile 2006 GENETIC EVALUATION Schena M, Angelini F, Bertetto O. Department of Medical.
Lecture 22 Cancer Genetics II: Inherited Susceptibility to Cancer Stephen B. Gruber, MD, PhD November 19, 2002.
Mechanisms and Epidemiology of Colon Cancer
Genetics and Primary Care
Hereditary Colorectal Cancer: An Overview Felice Schnoll-Sussman,MD Jay Monahan Center for Gastrointestinal Health New York Hospital/ Weill Cornell Medical.
About these slides SPEC – Short Presentation in Emerging Concepts
Familial Colorectal Cancers Francis M. Giardiello, M.D. The Johns Hopkins University.
Genetics of Colorectal Cancer
Comprehensive IHC Screening for Lynch Syndrome: What You Need to Know Andrea Lewis, MS, CGC January 14, 2010.
Kalyani Maganti, M.D. ASCO Chromosomes, DNA, and Genes Cell Nucleus Chromosomes Gene Protein.
Morning Report May 20, 2009 Bridger Clarke  Born in Lawrence, Massachusetts, on 4 January  Dropped out of high school at the age of fourteen.
Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
MLH 1 and Hereditary Nonpolyposis Colorectal Cancer
Cancer Genetics for Primary Care Sara Levene Registered Genetic Counsellor.
Development of a genetic model predicting the carrier status for mmr-gene mutations Fabio Marroni 1, Piero Benatti 2, Mariapina Montera 3, Daniela Barana.
An Accurate Genetic Model for Predicting the Carrier Status of mmr-gene Mutations Fabio Marroni 1, Piero Benatti 2, Mariapina Montera 3, Daniela Barana.
 2 nd overall leading cause of cancer death in the United States › 3 rd in each sex  Approximately 6% of individuals in the US will develop a cancer.
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Joint Hospital Surgical Grand Round 19 June 2004.
Update on Colon Cancer Screening and Prevention
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Genetics & Colorectal Cancer
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Genetics of Colorectal Cancer
Genetics and Ovarian Cancer June 16, 2015 Ovarian Cancer Alliance of Oregon and SW Washington Becky Clark, MS, CGC Genetic Counselor.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Colonoscopy; Surveillance Indications
COLORECTAL CANCER SCREENING in December of 2002 Jeffrey W. Frank, MD.
ANDREW LATCHFORD BSc, MBBS, MD, FRCP CONSULTANT GASTROENTEROLOGIST
Genetics and Cancer Sreekala Seepana. Overview Genetics and cancer Breast / Bowel cancers Breast / bowel cancer screening Clinical genetics referral Cases.
Angelina Jolie The White Coat Wonder. Rational  The purpose of our research is to enrich the Premed-A community with the knowledge of other cancers caused.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Genetic-Environmental Interaction: Implications for Osteoporosis Prevention Strategies.
Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
What are Microsatellites? D2S123 TAGGCCACACACACACACACA Unique Primer Mono, di, tri, tetra nucleotide repeats HNPCC - Expansion/contraction of nl repeats.
The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Screening Puja Myles
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Slides last updated: March 2015 CRC: RISK FACTORS.
Genetic predisposition to
Colonic cancer screening in high risk groups
What’s the Difference? Genetic and Common Diseases.
Paolo Vineis University of Torino and ISI Foundation, Torino, Italy address: GENE-ENVIRONMENT INTERACTIONS IN CANCER.
Do you have 3 or more affected relatives? (2 or less)
Colorectal cancer Screening and Prevention Dr malek Alhamidi
EMGO Institute for Health and Care Research Quality of Care Martina Cornel Professor of Community Genetics & Public Health Genomics Genomics in health.
Quality of Colonoscopy Using an endoscopic database to measure and improve quality AAPCE Memphis- November 5, 2011 David Lieberman MD Chief, Division of.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Hereditary Colorectal Cancer:
Lynch Syndrome or Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
Colonoscopic Polypectomy and Long-Term Prevention of Colorectal- Cancer Deaths N ENG J MED ;8 : Ann G. Zauber, Ph.D, Sidney J. Winawer,
Screening for Ovarian Cancer
27th Annual Winter CME Conference
EPIDEMIOLOGY.
What are Microsatellites?
Hereditary Colorectal Cancer: From Genetic Testing to Prevention
Lynch syndrome (LS) Hereditary Non-polyposis Colorectal Cancer (HNPCC)
Supporting Patients With Colorectal Cancer
Presentation transcript:

Familial Risk and Surveillance of Colon and Rectum Malcolm Dunlop Academic Coloproctology & Colon Cancer Genetics Group University of Edinburgh & Western General Hospital

Providing benefit Doing harm

Know your enemy!

Colorectal Cancer Aetiology Diet Age/Sex Lifestyle factors Chronic inflammatory bowel disease Genetic factors High penetrance dominant/recessive gene disorders Low penetrance dominant/recessive alleles Genetic risk factors, gene-environment & gene-gene interaction

Colorectal cancer age distribution

Absolute 5-year Colorectal Cancer Risk

Age-specific incidence rate (per 100,000 person-years) OR = 1.6, M vs F

Relative Contributions to Colorectal Cancer Incidence 35% - Lichtenstein NEJ M 2000

GeneContribution Familial adenomatous polyposis APC0.07% Rare dominant genetic syndromes <0.01% Peutz-Jegher’s Syndrome STK11/LKB1 Juvenile polyposis SMAD4, BMPR1A, PTEN HNPCCMMR 2.8% Recessive disorders Multiple adenoma phenotypeMUTYH~0.05% Familial E-Cadherin, TGF-BRII, ?15q ? Low penetrance alleles EpHx, GSTMI, GSTTI, NAT, CCND1 MTHFR, CYP1A1, CYP1A1 ? APC-I1307K, APC-E1317Q, Hras Gene-environment interaction APC-D1822V/fatRR 0.2 MTHFR-A226V/folateRR 0.8 Gene defects contributing to incidence GeneContribution Familial adenomatous polyposis APC0.07% Rare dominant genetic syndromes <0.01% Peutz-Jegher’s Syndrome STK11/LKB1 Juvenile polyposis SMAD4, BMPR1A, PTEN HNPCCMMR 2.8% Recessive disorders Multiple adenoma phenotypeMUTYH~0.05%

HNPCC kindred Bowel cancer Uterine cancer Stomach cancer 50% risk

HNPCC is due to mutations in DNA mismatch repair genes DNA mismatch LocalisationProportion of repair gene all mutations identified MLH13p2154% MSH22p1636% MSH62p16 ~10% ? Contribution of PMS2, MLH3, MSH3

Lifetime cancer risk for people with HNPCC gene mutations Large bowel Male80% Female30% Uterus (endometrium)40% Ovary9% Stomach19% Upper Urinary Tract10% Small intestine1%

Age (years) Cumulative risk % MMR gene penetrance * * Dunlop et al 1997

Effect of Surveillance on Colorectal Cancer Incidence and Mortality Retrospective case-control study colonoscopic surveillance vs no screen  62% colorectal cancer incidence  65% colorectal cancer mortality Jarvinen 2000

Effectiveness of Polypectomy by Risk Group

Evidence Base for Cancer Surveillance in HNPCC/MMR Carriers Beneficial?Grade of evidence Colorectal cancerYesB/C EndometrialNoB/C Ovarian?C Urothelial?C GastricNoB/C Brain?C

Empiric FH Criteria to Guide Surveillance 71 53

Familial aggregation due to chance Familial aggregation due shared environment Recall inaccuracy (+ve or –ve) Effect of family size Inability to determine risk at the individual level Inherent limitations of FH information

Heterogeneity of CRC Risk Aggregate risk 1: Several modest risk subjects 3 cases from HNPCC families Single MMR gene carrier Pop n risk

Population Prevalence of Colorectal Cancer FH Published data* Any affected relative % 1 affected under 45yrs0.4% 2 affected relatives0.2% Combined0.5% *St John. Ann Int Med Fuchs NEJM Bonelli Int J C Slattery JNCI Ponz de Leon Cancer Stephenson. BJS 1991

Edinburgh FH Study Population Prevalence of Family History All relatives traced of healthy control subjects (n = 160) (age years) Family History Criteria Any affected relative % ( 95% CI = 21.7, 35.8 ) Affected first degree relative % ( 95% CI = 4.9, 13.9 ) More than one affected relative % ( 95% CI = 4.4, 13.1 ) Mitchell & Dunlop 2004 unpublished.

Accuracy of FH Reporting Knowledge of Family Member’s Health Interviewee GroupRelative GroupTotal Number of Relatives Number (%) For Whom Interviewee Could Supply Any Health Information Cases (n=199)First degree relatives (95%) “Second degree relatives (36%) Controls (n=133)First degree relatives (96%) “Second degree relatives (51%)

Accuracy of FH Reporting Reporting of Colorectal Cancer in Relatives

FH Criteria (ACP/BSG) Two affected first degree relatives or One first degree relative affected at <45yrs Families meeting criteria on interview data alone5 Validated by record linkage2 Positive Predictive Value 0.40 (95% CI = ) Record linkage identified families not reported at interview 4 Sensitivity of interview 0.33 (95% CI = ) Accuracy of FH Reporting PPV and sensitivity for ACP criteria

Family history of colorectal cancer is common in population FH of colorectal cancer is substantially under-reported Interviewee reports are subject to considerable inaccuracy Interview data should be interpreted with caution FH Reporting at Interview Conclusions

Degree of empirical lifetime CRC risk RR and OR

Absolute 10yr Risk Current age Population CRC risk 1/3,0001/6001/1701/73 CRC risk if FH++1/5001/1001/901/36 Chance of 2yrly colonoscopy 1/9001/1801/1601/65 preventing CRC death (FH++) Cumulative risk for each age group

Absolute 10yr Colorectal Cancer Risk Current age UK Population Moderate risk FH MMR carrier

Competing Causes of Death 10-year risks by age-group 50-69yrs70yrs+ All cause death17%41% Developing CRC 1.7%4.2% Death from CRC0.95%2.6%

Colonoscopy adverse events OutcomeRisk/examination Adenoma miss rate (Rex et al 1997) Overall27% 6-9mm13% >1cm6% Serious morbidity0.3% Mortality1/5000-1/10,000

Projected effect of surveillance ACP/BSG Moderate Risk Guidelines Projected benefit Single colonoscopy 35-45yrs 55yrs Early CRC detection 1:1660 1:180 Prevention CRC death 1:3600 1:220 Detect polyposis syndromes ++ +/- Reduce anxiety ++ +/- Identify polyp formers for surveillance + ++ Sporadic CRC incidence reduction - +/-

Edinburgh FH Genetic Database High Moderate Low Unclear 18% 40% 33% 9% N = 882

Prevalence colonoscopy screen (n=448 consultands. 176 Medium/High Risk) Bradshaw et al. Gut 2003; 52:

Possession of a technology requires that you keep your eye on the horizon!

Conclusions u Limited high quality data available to inform practice u Centralised management of FH+ cases facilitates risk assignment and audit of outcomes u People fulfilling moderate risk criteria merit surveillance on two occasions, aged and at 55yrs u Whole colon should be imaged u People assigned low risk can be reassured and population interventions advised